|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Peptide sequence around phosphorylation site of tyrosine 1007 (K-E-Y(p)-Y-K) derived from Human JAK2.|
|Storage buffer||PBS, pH 7.4, with 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for Western blot is HT29 cells; suggested positive control for IHC is human breast carcinoma.
Janus Activating Kinase 2 (JAK2) is one of a number of related tyrosine kinases involved in cytoplasmic signal transduction. In response to a varitety of cytokine or related factors (e.g., interferon, interleukins), JAKs are activated via phosphorylation at 2 adjacent tyrosine residues. The activation of JAKs can lead to the phosphorylation of STAT (signal transducers and activatiors of transcription) proteins, which dimerize and translocate to the nucleus. Once translocated to the nucleus, the STAT proteins can modify transcription of numerous genes, including interferon-stimulated genes. JAK2 is required for the IFN gamma-receptor complex initiation and JAK1 functions as an amplifier. However, active JAK1 may be required for complex responses. Some studies have suggested that the role of JAK2 might be performed by Tyk2 and JAK3, if they were positioned correctly within the IFN gamma-receptor complex. Plays a role in leptin signaling and control of body weight.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.